Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814);Discovery and clinical introduction of first-in-class imipridone ONC201

Oncotarget

Volumn 7, Issue 45, 2016, Pages 74380-74392

  Allen, Joshua E ^a   Kline, C Leah B ^b   Prabhu, Varun V ^a   Wagner, Jessica ^b   Ishizawa, Jo ^c   Madhukar, Neel ^d   Lev, Avital ^b   Baumeister, Marie ^b   Zhou, Lanlan ^b   Lulla, Amriti ^b   Stogniew, Martin ^a   Schalop, Lee ^a   Benes, Cyril ^e,f   Kaufman, Howard L ^g   Pottorf, Richard S ^h   Rao Nallaganchu, B ^h   Olson, Gary L ^h   Al Mulla, Fahd ⁱ   Duvic, Madeleine ^c   Wu, Gen Sheng ^j   Dicker, David T ^b   Talekar, Mala K ^k   Lim, Bora ^c   Elemento, Olivier ^d   Oster, Wolfgang ^a   Bertino, Joseph ^g   Flaherty, Keith ^e,f   Wang, Michael L ^c   Borthakur, Gautam ^c   Andreeff, Michael ^c   Stein, Mark ^g   El Deiry, Wafik S ^b   more..

^a Oncoceutics   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^h Provid Pharmaceuticals   (United States)

ⁱ KUWAIT UNIVERSITY   (Kuwait)

^j KARMANOS CANCER INSTITUTE   (United States)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

more..

Author keywords

ATF4; DRD2; Integrated stress response; ONC201; TIC10

Indexed keywords

7 BENZYL 4 (2 METHYLBENZYL) 1,2,6,7,8,9 HEXAHYDROIMIDAZO[1,2 A]PYRIDO[3,4 E]PYRIMIDIN 5(AH)ONE; ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CYTARABINE; DACARBAZINE; DEATH RECEPTOR 5; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IBRUTINIB; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PACLITAXEL; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; SORAFENIB; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VENETOCLAX; FUSED HETEROCYCLIC RINGS; TIC10 COMPOUND;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER STEM CELL; COLORECTAL CANCER; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INACTIVATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHARMACODYNAMICS; RADIOSENSITIVITY; RECEPTOR UPREGULATION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; ANIMAL; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; NEOPLASMS;

EID: 84995802992     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.28012     Document Type: Erratum

References (47)

1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013; 5: 171ra17. doi: 10.1126/scitranslmed.3004828.
2. Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015; 14: 99. doi: 10.1186/s12943-015-0346-9.
3. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology. 2009; 127: 145-54. doi: 10.1111/j.1365-2567.2009.03058.x.
4. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem. 2002; 277: 47928-37. doi: 10.1074/jbc.M207509200.
5. Xuan Z, Zhang MQ. From worm to human: bioinformatics approaches to identify FOXO target genes. Mech Ageing Dev. 2005; 126: 209-15. doi: 10.1016/j.mad.2004.09.021.
6. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008; 10: 138-48. doi: 10.1038/ncb1676.
7. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016; 9: ra17. doi: 10.1126/scisignal.aac4380.
8. Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases. Sci Signal. 2016; 9: ra18. doi: 10.1126/scisignal.aac4374.
9. Ait Ghezala H, Jolles B, Salhi S, Castrillo K, Carpentier W, Cagnard N, Bruhat A, Fafournoux P, Jean-Jean O. Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5' short ORFs. Nucleic Acids Res. 2012; 40: 9557-70. doi: 10.1093/nar/gks762.
10. Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, Yuan CL, Krokowski D, Wang S, Hatzoglou M, Kilberg MS, Sartor MA, Kaufman RJ. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol. 2013; 15: 481-90. doi: 10.1038/ncb2738.
11. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005; 65: 5662-7. doi: 10.1158/0008-5472.CAN-05-0693.
12. Zou W, Yue P, Khuri FR, Sun SY. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008; 68: 7484-92. doi: 10.1158/0008-5472.CAN-08-1318.
13. B'Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P, Bruhat A. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 2013; 41: 7683-99. doi: 10.1093/nar/gkt563.
14. Endo Greer Y, Lipkowitz S. ONC201: Stressing tumors to death. Sci Signal. 2016; 9: fs1. doi: 10.1126/scisignal. aad7955.
15. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 2005; 24: 1243-55. doi: 10.1038/sj.emboj.7600596.
16. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 2003; 300: 1574-7. doi: 10.1126/science.1079817.
17. Madhukar NS, Elemento O, Benes CH, Garnett MJ, Stein M, Bertino JR, Kaufman HL, Arrillaga-Romany I, Batchelor TT, Schalop L, Oster W, Stogniew M, Andreeff M, et al. D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract nr LB-209. AACR; 2016 Abstract nr LB-209.
18. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149: 1284-97. doi: 10.1016/j.cell.2012.03.049.
19. Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 2014; 5: 882-93. doi: 10.18632/oncotarget.1801.
20. Meredith EJ, Holder MJ, Rosen A, Lee AD, Dyer MJ, Barnes NM, Gordon J. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci U S A. 2006; 103: 13485-90. doi: 10.1073/pnas.0605993103.
21. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011; 10: 47-60. doi: 10.1038/nrd3320.
22. Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010; 5: e11865. doi: 10.1371/journal.pone.0011865.
23. Kline CL, Lulla AR, Dicker DT, Allen JE, El-Deiry WS. TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis. Cancer Res. 2015; 75: 2942. doi: doi: 10.1158/1538-7445.AM2015-2942.
24. Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle. 2015; 14: 2422-8. doi: 10.1080/15384101.2015.1054086.
25. Prabhu VV, Lulla AR, Wagner JM, Hernandez-Borrero LJ, Talekar MK, Kline CL, Dicker DT, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins. Blood. 2014; 124: 5237.
26. Duvic M, Zhang X, Ni X, Langridge T, Tarapore R, Allen JE. ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling. Blood. 2015; 126: 4011.
27. Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014; 13: 3331-5. doi: 10.4161/15384101.2014.965061.
28. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 2011; 17: 4019-30. doi: 10.1158/1078-0432.CCR-11-0075.
29. Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol. 2007; 60: 777-87. doi: 10.1007/s00280-007-0424-9.
30. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010; 100: 95-103. doi: 10.1007/s11060-010-0143-7.
31. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015; 75: 1423-32. doi: 10.1158/0008-5472.CAN-13-3451.
32. Qiu H, Fang X, Luo Q, Ouyang G. Cancer stem cells: a potential target for cancer therapy. Cell Mol Life Sci. 2015; 72: 3411-24. doi: 10.1007/s00018-015-1920-4.
33. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17: 313-9. doi: 10.1038/nm.2304.
34. Prabhu VV, Ishizawa J, Zhao D, Allen JE, Batchelor TT, Chi AS, Andreeff M, El-Deiry WS. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood. 2014; 124: 5219.
35. Karpel-Massler G, Ba M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget. 2015; 6: 36456-71. doi: 10.18632/oncotarget.5505.
36. Allen JE, Crowder R, El-Deiry WS. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS One. 2015; 10: e0143082. doi: 10.1371/journal.pone.0143082.
37. He C, Lao WF, Hu XT, Xu XM, Xu J, Fang BL. Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects. World J Gastroenterol. 2004; 10: 654-9.
38. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol. 2003; 22: 1241-5.
39. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosisinducing ligand (TRAIL) gene. Cancer Res. 2001; 61: 3330-8.
40. Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015; 75: 1668-74. doi: 10.1158/0008-5472. CAN-14-2356.
41. Zhang Q, Wang H, Ran L, Zhang Z, Jiang R. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun. 2016; 476: 260-6. doi: 10.1016/j.bbrc.2016.05.106.
42. Stein MN, Mayer TM, Moss RA, Silk AW, Chan N, Haffty BG, DiPaola RS, Beckett Y, Bentlyewski E, Zheng L, Fang B, Allen JE, Mehnert JM. First-in-human dose escalation study of oral ONC201 in advanced solid tumors. J Clin Oncol. 2015; 33.
43. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 2108-21. doi: 10.1200/JCO.2004.02.106.
44. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25: 4293-7. doi: 10.1200/JCO.2007.11.4207.
45. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667-75. doi: 10.1200/JCO.2005.03.108.
46. Manochakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist. 2007; 12: 978-90. doi: 10.1634/theoncologist.12-8-978.
47. Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathwayinducing compound, determines its potent anti-cancer activity. Oncotarget. 2014; 5: 12728-37. doi: 10.18632/oncotarget.2890.